Who is sponsoring NCT01523860?

NCT01523860 is sponsored by Fondazione Italiana Linfomi - ETS.

What drugs are being tested in NCT01523860?

Interventions in NCT01523860: Rituximab, Mitoxantrone, Bendamustine.

What condition does NCT01523860 study?

NCT01523860 studies Follicular Lymphoma.

Is NCT01523860 still recruiting?

NCT01523860 is currently completed. Last updated 29 February 2016.

Last reviewed 2016-02-29 · How we verify

NCT01523860: FLE09

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brief Induction Chemoimmunotherapy With Rituximab + Bendamustine + Mitoxantrone Followed by Rituximab in Elderly Patients With Advanced Stage Previously Untreated Follicular Lymphoma

Completed Phase 2 Last updated 29 February 2016

What this trial tests

Phase 2 trial testing Rituximab, Mitoxantrone, Bendamustine in Follicular Lymphoma in 76 participants. Completed in 1 January 2015.

Timeline

1 June 2009

Primary endpoint
1 January 2015

1 January 2015

Quick facts

Lead sponsor	Fondazione Italiana Linfomi - ETS
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	1 June 2009
Primary completion	1 January 2015
Estimated completion	1 January 2015
Sites	37 locations across Italy

Drugs / interventions tested

Rituximab, Mitoxantrone, Bendamustine — full drug profile →

Conditions studied

Follicular Lymphoma — all drugs for Follicular Lymphoma →

Sponsor

Fondazione Italiana Linfomi - ETS — full company profile →

Who can join

Adults 65 to 80, any sex, with Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete Response (CR) Rate at the end of the consolidation phase
Time frame: 6 months
Proportion of CR according to the Cheson 2007 response criteria

Sponsor's own description

This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a brief chemoimmunotherapy with the combination of Rituximab + Bendamustine + Mitoxantrone in elderly patients with advanced stage Follicular Lymphoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy.
Wang T, Suita Y, Miriyala S, Dean J, et al · · 2021 · cited 33× · PMID 33918635 · DOI 10.3390/pharmaceutics13040520

Verify or expand the search:

Other recruiting trials for Follicular Lymphoma

Currently open trials in the same condition.

NCT07128641 — Odronextamab in Low Tumor Volume Advanced FL · Phase 2 · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT07126678 — Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma · NA · recruiting
NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting

Other Fondazione Italiana Linfomi - ETS trials

Trials by the same sponsor.

NCT07453095 — Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy · Phase 2 · not yet recruiting
NCT07256158 — PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma · Phase 3 · not yet recruiting
NCT07207785 — PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma · Phase 2 · not yet recruiting
NCT06781359 — Study on Plasmablastic Lymphoma Patients · recruiting
NCT06492837 — Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01523860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Italiana Linfomi - ETS
Last refreshed: 29 February 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01523860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing